Fort Worth Star-Telegram

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / August 3, 2023 / CAGE Bio, Inc. (hereinafter "CAGE Bio") a biotechnology company focused on developing innovative drug therapies for localized ...
KXAN

CAGE Bio Announces Collaboration to Advance First-in-Class Treatments for Cutaneous Graft versus Host Disease

SAN CARLOS, Calif. and DALLAS, Aug. 27, 2025 /PRNewswire/ -- CAGE Bio Inc., a leader in advancing innovative therapies for targeted and localized treatment of immunological skin diseases, today ...
KXAN

CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological ...
abc27

CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment

SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today ...
The Business Journals

Pegasus Park lands Silicon Valley startup focused on skin treatments

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The latest company to arrive at ...